bluebird bio (BLUE) Posts Wider-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
bluebird bio Reports Third Quarter 2015 Financial Results and Recent Operational Progress
November 4, 2015 4:09 PM EST-- Six abstracts accepted for presentation at American Society of Hematology (ASH) Annual Meeting --
-- Increased enrollment target for HGB-206 study of LentiGlobin® in severe sickle cell disease (SCD) from eight patients to 20 patients -
-- Published a paper on megaTAL genome editing platform in Science Translational Medicine with collaborators at Seattle Childrens Research Institute --
-- Ended quarter with $901.7 million in cash, cash equivalents, and marketable securities --
-- Company will discuss ASH... More
